Neurocrine Biosciences (FRA:NB3) Total Liabilities : €999 Mil (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Neurocrine Biosciences Total Liabilities?

Neurocrine Biosciences's Total Liabilities for the quarter that ended in Mar. 2024 was €999 Mil.

Neurocrine Biosciences's quarterly Total Liabilities increased from Sep. 2023 (€792.80 Mil) to Dec. 2023 (€934.79 Mil) and increased from Dec. 2023 (€934.79 Mil) to Mar. 2024 (€999.40 Mil).

Neurocrine Biosciences's annual Total Liabilities increased from Dec. 2021 (€618.17 Mil) to Dec. 2022 (€623.89 Mil) and increased from Dec. 2022 (€623.89 Mil) to Dec. 2023 (€934.79 Mil).

Neurocrine Biosciences Total Liabilities Historical Data

The historical data trend for Neurocrine Biosciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences Total Liabilities Chart

Neurocrine Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

602.19

500.19

618.17

623.89

934.79

Neurocrine Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															630.73	701.57	792.80	934.79	999.40

Neurocrine Biosciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Neurocrine Biosciences's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	600.452	+	(236.861	+	97.477
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	935

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	2981.534	-	2046.744
	=	935

Neurocrine Biosciences's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	655.868	+	(232.668	+	110.86
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	999

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	3194.608	-	2195.212
	=	999

Neurocrine Biosciences Total Liabilities Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurocrine Biosciences (FRA:NB3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (FRA:NB3) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

NBIX:USA N1BI34:Brazil

Address

12780 El Camino Real, San Diego, CA, USA, 92130

Website

https://www.neurocrine.com

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Neurocrine Biosciences (FRA:NB3) Headlines

No Headlines